Agios Pharmaceuticals AGIO AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's afs and trading securities - unrealized loss position (<12 months) accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- Agios Pharmaceuticals (AGIO) reported AFS and trading securities - unrealized loss position (<12 months) accumulated loss of 112 in Q1 2026.
- How has Agios Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss changed year-over-year?
- Agios Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss decreased by 28.2% year-over-year, from 156 to 112.
- What is the long-term trend for Agios Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) accumulated loss has grown at a -15.7% compound annual growth rate (CAGR), from 87 to 37.